Zimbabwe has turned down a major US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to Washington's demand for sensitive data.
This move became public after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa believed the deal was "lopsided".
An official spokesman has since explained that the United States was seeking genetic material for scientific study and commercial gain while refused to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for more negotiations to find a deal acceptable to all parties so the country's vital HIV programme can be sustained.
Wider Background
This development comes after a similar case in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were raised about the safety of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government agreements to enhance transparency and responsibility.
As per statements, 16 African countries have to date signed these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that shared data," his statement read.
"In essence, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our people should a future pandemic emerge."
Sovereignty and Global Health
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining frameworks already established via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is designed to guarantee that when a country provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We welcome further discussions with our American counterparts on how subsequent collaboration might be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body stated it understood the government's concerns, but suggested that negotiations should continue considering much of the country's Aids initiatives depended on external financing.
"If specific concerns exist, including those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group commented.
This impasse highlights the ongoing tensions between accepting much-needed foreign assistance and protecting local interests in an increasingly data-driven world.